

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A method for improving glucose intolerance comprising administering to a subject in need thereof an effective amount of a chymase inhibitor, wherein the chymase inhibitor is 4-(1-((4-methylbenzo[b]thiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid.
2. (previously presented): The method according to claim 1, wherein the method is for treatment of diseases caused by glucose intolerance.
- 3.-39. (canceled).
40. (new): The method according to claim 2, wherein the diseases caused by glucose intolerance are diabetes and/or diabetes complications.
41. (new): The method according to claim 40, wherein the diabetes complications are diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction or obesity.

42. (new): The method according to claim 40, wherein the diabetes complications are diabetic nephropathy, diabetic retinopathy or diabetic peripheral neuropathy.

43. (new): The method according to claim 1 further comprising administering an ACE inhibitor.